A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Status:
RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).